Products and Services - MACS Flow Cytometry - Reagents - MACS Antibodies - Anti-PTK7 (CCK-4) antibodies, human

Anti-PTK7 (CCK-4) antibodies, human (clone: 188B)

Overview

The Anti-PTK7 (CCK-4) antibody (clone 188B) recognizes human protein tyrosine kinase-7 (PTK7). PTK7, also known as colon carcinoma kinase-4 (CCK-4), is a receptor protein tyrosine kinase (RPTK)-like molecule that contains a catalytically inactive tyrosine kinase domain.1,2 PTK7 was identified to be important for neural development as a regulator of planar cell polarity, being required for convergent extension movement and neural tube closure.3 Using the Anti-PTK7 (CCK-4) antibody, PTK7 expression was recently analyzed on blood and bone marrow cells. PTK7 was shown to be expressed on plasmacytoid dendritic cells, CD141 (BDCA-3)high type-2 myeloid dendritic cells, and CD34+ hematopoietic progenitor cells (HPCs). PTK7 was detected on early (CD34+ CD133+) and late (CD34+ CD133) HPCs. In tonsils, PTK7 was also found on some T cells.

Technical data


Clone 188B
Isotype mouse IgG2a
Isotype control For the appropriate isotype control antibody, please refer to the tab Related items.
Alternative names of antigen
Entrez Gene ID 5754
Molecular mass of antigen [kDa] 115
Cross-reactivity
Distribution of antigen
Product format Antibodies are supplied in buffer containing stabilizer and 0.05% sodium azide.
Storage Store protected from light at 2–8 °C. Do not freeze.
Available conjugates PE, APC, Biotin, pure

Gallery

Figure 1

Human PBMCs were stained with Anti-PTK7-APC and CD303 (BDCA-2)-FITC, CD141 (BDCA-3)-PE, or CD34-FITC, respectively. Cells were analyzed by flow cytometry. Plasmacytoid dendritic cells (PDCs) are identified by CD303 (BDCA-2), type-2 myeloid dendritic cells (MDC2s) by CD141 (BDCA-3), and hematopoietic stem cells (HPCs) by CD34 expression.
Identification of PTK7+ CD303 (BDCA-2)+ PDCs
Identification of PTK7+ CD141 (BDCA-3)high MDC2s
Identification of PTK7+ CD34+ HPCs

Related Items

Library

Selected references

  1. Mossie et al. (1995) Oncogene 11: 2179–2184.
  2. Park et al. (1996) J. Biochem. 119: 235–239.
  3. Lu et al. (2004) Nature 430: 93–98.

Product Order no. Price

Anti-PTK7 (CCK-4)-PE, human (clone: 188B)

For research use only
Capacity: for 30 tests (1)

Capacity

(1)One test corresponds to labeling of up to 107 cells in a total volume of 100 µL.
 
Data sheet
130-099-109 $90.00 cart

Anti-PTK7 (CCK-4)-PE, human (clone: 188B)

For research use only
Capacity: for 100 tests (1)

Capacity

(1)One test corresponds to labeling of up to 107 cells in a total volume of 100 µL.
 
Data sheet
130-091-364 $255.00 cart

Anti-PTK7 (CCK-4)-APC, human (clone: 188B)

For research use only
Capacity: for 30 tests (1)

Capacity

(1)One test corresponds to labeling of up to 107 cells in a total volume of 100 µL.
 
Data sheet
130-099-660 $115.00 cart

Anti-PTK7 (CCK-4)-APC, human (clone: 188B)

For research use only
Capacity: for 100 tests (1)

Capacity

(1)One test corresponds to labeling of up to 107 cells in a total volume of 100 µL.
 
Data sheet
130-091-366 $275.00 cart

Anti-PTK7 (CCK-4)-Biotin, human (clone: 188B)

For research use only
Capacity: for 30 tests (1)

Capacity

(1)One test corresponds to labeling of up to 107 cells in a total volume of 100 µL.
 
Data sheet
130-100-176 $75.00 cart

Anti-PTK7 (CCK-4)-Biotin, human (clone: 188B)

For research use only
Capacity: for 100 tests (1)

Capacity

(1)One test corresponds to labeling of up to 107 cells in a total volume of 100 µL.
 
Data sheet
130-091-365 $215.00 cart

Anti-PTK7 (CCK-4) pure, human (clone: 188B)

For research use only
Content: 100 µg in 1 mL

Capacity

(1)One test corresponds to labeling of up to 107 cells in a total volume of 100 µL.
 
Data sheet
130-091-578 $120.00 cart

Customer login

Go

Forgot password?
Register for account

0 Shopping cart

Contact

Miltenyi Biotec Inc.
Phone: +1 800 FOR MACS
Fax:+1 530 745 2806
macs@miltenyibiotec.com
Contact overview

Product finder

Toolbox

New filling format for mouse and rat antibodies!

New filling format for mouse and rat antibodies!

Change country

Please select your country to continue